Label-retaining assay enriches tumor-initiating cells in glioblastoma spheres cultivated in serum-free medium

Oncology Letters

Volumn 12, Issue 2, 2016, Pages 815-824

  Zeng, Lingcheng ^a   Zhao, Yiqing ^a   Ouyang, Taohui ^a   Zhao, Tianyuan ^a   Zhang, Suojun ^a   Chen, Jian ^a   Yu, Jiasheng ^a   Lei, Ting ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer stem cell; DiI; Glioma; Label retaining assay; Label retaining cell

Indexed keywords

BETA 3 TUBULIN; BETA TUBULIN; CD133 ANTIGEN; DII DYE; FLUORESCENT DYE; GLIAL FIBRILLARY ACIDIC PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENICITY; CELL ASSAY; CELL PROLIFERATION; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; GLIOMA STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; LABEL RETAINING ASSAY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STEM CELL SELF-RENEWAL; WESTERN BLOTTING;

EID: 84977080692     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4690     Document Type: Article

References (37)

1. Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O’Neill B and Faul C: A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a non-trial population of the results of a randomised Phase III clinical trial: Has a more radical approach improved survival? Br J Radiol 85: e729-e733, 2012.
2. Jackson M, Hassiotou F and Nowak A: Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target. Carcinogenesis 36: 177-185, 2015.
3. Stopschinski BE, Beier CP and Beier D: Glioblastoma cancer stem cells-from concept to clinical application. Cancer Lett 338: 32-40, 2013.
4. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
5. Wang J, Sakariassen PØ, Tsinkalovsky O, Immervoll H, Bøe SO, Svendsen A, Prestegarden L, Røsland G, Thorsen F, Stuhr L, et al: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122: 761-768, 2008.
6. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U and Beier CP: CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67: 4010-4015, 2007.
7. Ogden AT, Wziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, et al: Identification of A2B5+CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 62: 505-514, 2008.
8. Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, Fei Z, Zhen HN, You SW and Yang H: Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol 2: 247-257, 2009.
9. Ma I and Allan AL: The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306, 2011.
10. Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, Bayani J, Pressey JC, Lionel AC, Clarke ID, et al: Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci USA 112: 851-856, 2015.
11. Clément V, Marino D, Cudalbu C, Hamou MF, Mlynarik V, de Tribolet N, Dietrich PY, Gruetter R, Hegi ME and Radovanovic I: Marker-independent identification of glioma-initiating cells. Nat Methods 7: 224-228, 2010.
12. Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, Offner S, Dunant CF, Eshkind L, Bockamp E, et al: Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135: 1118-1129, 2008.
13. Radford IR and Lobachevsky PN: An enteroendocrine cell-based model for a quiescent intestinal stem cell niche. Cell Prolif 39: 403-414, 2006.
14. Glauche I, Moore K, Thielecke L, Horn K, Loeffler M and Roeder I: Stem cell proliferation and quiescence-two sides of the same coin. PLoS Comput Biol 5: e1000447, 2009.
15. Hussein D, Punjaruk W, Storer LC, Shaw L, Othman R, Peet A, Miller S, Bandopadhyay G, Heath R, Kumari R, et al: Pediatric brain tumor cancer stem cells: Cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro Oncol 13: 70-83, 2011.
16. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
17. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
18. Progatzky F, Dallman MJ and Lo Celso C: From seeing to believing: Labelling strategies for in vivo cell-tracking experiments. Interface Focus 3: 20130001, 2013.
19. Fernandez-Gonzalez R, Illa-Bochaca I, Shelton DN, Welm BE, Barcellos-Hoff MH and Ortiz-de-Solorzano C: In situ analysis of cell populations: Long-term label-retaining cells. Methods Mol Biol 621: 1-28, 2010.
20. van der Wath RC, Wilson A, Laurenti E, Trumpp A and Liò P: Estimating dormant and active hematopoietic stem cell kinetics through extensive modeling of bromodeoxyuridine label-retaining cell dynamics. PLoS One 4: e6972, 2009.
21. Moore N, Houghton J and Lyle S: Slow-cycling therapy-resistant cancer cells. Stem Cells Dev 21: 1822-1830, 2012.
22. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T and Herlyn M: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594, 2010.
23. Gao MQ, Choi YP, Kang S, Youn JH and Cho NH: CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29: 2672-2680, 2010.
24. Dembinski JL and Krauss S: Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 26: 611-623, 2009.
25. Deleyrolle LP, Harding A, Cato K, Siebzehnrubl FA, Rahman M, Azari H, Olson S, Gabrielli B, Osborne G, Vescovi A and Reynolds BA: Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 134: 1331-1343, 2011.
26. Richichi C, Brescia P, Alberizzi V, Fornasari L and Pelicci G: Marker-independent method for isolating slow-dividing cancer stem cells in human glioblastoma. Neoplasia 15: 840-847, 2013.
27. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, et al: A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17: 362-375, 2010.
28. Lottaz C, Beier D, Meyer K, Kumar P, Hermann A, Schwarz J, Junker M, Oefner PJ, Bogdahn U, Wischhusen J, et al: Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 70: 2030-2040, 2010.
29. Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T and Park DM: The evidence of glioblastoma heterogeneity. Sci Rep 5: 7979, 2015.
30. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, et al: Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol 94: 1-19, 2009.
31. Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 10: R25, 2008.
32. Allan AL, Vantyghem SA, Tuck AB and Chambers AF: Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis 26: 87-98, 2007.
33. Udagawa T: Tumor dormancy of primary and secondary cancers. APMIS 116: 615-628, 2008.
34. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG and Parada LF: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526, 2012.
35. Trumpp A, Essers M and Wilson A: Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10: 201-209, 2010.
36. Wilson A, Laurenti E and Trumpp A: Balancing dormant and self-renewing hematopoietic stem cells. Curr Opin Genet Dev 19: 461-468, 2009.
37. Schillert A, Trumpp A and Sprick MR: Label retaining cells in cancer-the dormant root of evil? Cancer Lett 341: 73-79, 2013.